Dachaigh › Ailse Endometrial › Tennessee
Sgrùdaidhean clionaigeach Ailse Endometrial ann an Tennessee
Tha 40 sgrùdaidhean airson Ailse Endometrial a’ lorg phàirtichean aig làraichean ann an Tennessee.
Bailtean ann an Tennessee
Teacsa sgrùdaidh oifigeil (Beurla)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Vanderbilt-Ingram Cancer Center Cool Springs, Franklin
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 5 Dàmh 2026 · NCT07198074Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Regional Cancer Center at Johnson City Medical Center, Johnson City
- Ballad Health Cancer Care - Kingsport, Kingsport
- agus 3 a bharrachd
A’ fastadhÌre 2
Gach aois · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT05564377A Study of PHST001 in Advanced Solid Tumors
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06840886A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06270706The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT04585750A Phase 1 Study of the Safety and Tolerability of CTX-10726
- SCRI Oncology Partners, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT07419841A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06760819A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06172478A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
A’ fastadhÌre 1
Aoisean 19 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06586957DESTINY-PANTUMOUR04
- Research Site, Nashville
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 130 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07124000Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06218914Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Nashville
A’ fastadhÌre 2
Aoisean 18 gu 130 · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Sult 2026 · NCT05983432A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Erlanger Medical Center ( Site 5009), Chattanooga
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 17 Sult 2026 · NCT06952504A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Sarah Cannon Nashville, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT07109726A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT07213609Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT06293898Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 3 Sult 2026 · NCT07755436A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Vanderbilt-Ingram Cancer Center, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT06515613A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- SCRI Oncology Partners - Nashville, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 26 Lùna 2026 · NCT07383506Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
A’ fastadhÌre 1
Aoisean 15 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
A’ fastadhÌre 1/2
12 Months – 30 Years · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT04851119A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT07182149FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT05919264A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Lùna 2026 · NCT05592626A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Lùna 2026 · NCT06330064Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Lùna 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Tennessee Oncology, PLLC, Chattanooga
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Iuch 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Knoxville
- Research Site, Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 29 Iuch 2026 · NCT07044336A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- SCRI Oncology Partners, Nashville
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Iuch 2026 · NCT06695845First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- The West Clinic, PLLC dba West Cancer Center, Germantown
- Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 7 Iuch 2026 · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Ògmh 2026 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Ògmh 2026 · NCT07046923A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- SCRI Oncology Partners, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Ògmh 2026 · NCT07503808Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 6 Cèit 2026 · NCT06239194cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 agus nas sine · Gach gnè · Air ùrachadh 20 Faoi 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 28 Dàmh 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Tennessee Oncology, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Sult 2025 · NCT05941507A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Gearr 2025 · NCT05669430Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.